부산대학교 도서관

Schizophrenia is serious and prevalent psychotic condition in which patients misinterpret the real conditions and might cause combination of symptoms like hallucinations, delusions, and extremely disordered thinking and impaired behavior during daily functioning. People who are suffering from schizophrenia require lifelong treatment. The scientists are elucubrating round the clock to contribute novel pharmacological compounds in the hopes of improving the “quality of life” of schizophrenia patients. The antipsychotics drugs which are currently available in the market for management of schizophrenia needs reformulation into lipid vesicular nanocarrier systems with tremendous potential to provide superior platform as cutting-edge therapeutic strategies to target the brain via intranasal administration and thereby reduced the systemic adverse effects. The development of nanoformulation also provides sustained or prolonged drug delivery systems which might be helpful in reducing necessitate of frequent dosage administration. The transferosomes are types of vesicular nanocarriers which have been explored extensively in previous decades to address the flaws of conventional drug delivery systems and currently aregaining significant relevance in therapeutics owing to their capacity to conquer drug penetration challenges via biological membranes which acts by squeezing the vesicular structure into intercellular lipid barrier of biological membrane. The non-invasive intranasal delivery of drugs via nanotransferosomal vesicles acts as valuable tool for drugs with poor bioavailability. This review article addresses the risk factors for schizophrenia; key challenges faced with conventional medicines and the significance of nanotransferosomes in intranasal drug delivery for the management of schizophrenia which might advance the quality of living of patients suffering from schizophrenia.